HIV-1 and HIV-2 reverse transcriptases: Different mechanisms of resistance to nucleoside reverse transcriptase inhibitors

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5885-5894

  Boyer, Paul L ^a   Clark, Patrick K ^b   Hughes, Stephen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIDANOSINE; LAMIVUDINE; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE MONOPHOSPHATE; ZIDOVUDINE TRIPHOSPHATE;

ARTICLE; CHEMICAL REACTION; EXCISION PATHWAY VIRUS RESISTANCE MECHANISM; EXCLUSION PATHWAY VIRUS RESISTANCE MECHANISM; EXPERIMENTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PYROPHOSPHOROLYSIS; VIRUS IMMUNITY; VIRUS RESISTANCE; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84861313397     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06597-11     Document Type: Article

References (40)

1. Ahluwalia G, et al. 1987. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36:3797-3800.
2. Basavapathruni A, Anderson KS. 2007. Reverse transcription of the HIV-1 pandemic. FASEB J. 21:3795-3808.
3. Bofill M, Fairbanks LD, Ruckemann K, Lipman M, Simmonds HA. 1995. T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection. J. Biol. Chem. 270:29690-29697.
4. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
5. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. 2006. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog. 2:e10.
6. Boyer PL, Stenbak CR, Clark PK, Linial ML, Hughes SH. 2004. Characterization of the polymerase and RNase H activities of human foamy virus reverse transcriptase. J. Virol. 78:6112-6121.
7. Cohen A, Barankiewicz J, Lederman HM, Gelfand EW. 1983. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J. Biol. Chem. 258:12334-12340.
8. Deeks SG, et al. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537-1544.
9. Delviks-Frankenberry KA, et al. 2008. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. U. S. A. 105:10943-10948.
10. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. 1995. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 270: 29682-29689.
11. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2000. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 300:403-418.
12. Gotte M, Rausch JW, Marchand B, Sarafianos S, Le Grice SF. 2010. Reverse transcriptase in motion: conformational dynamics of enzymesubstrate interactions. Biochim. Biophys. Acta 1804:1202-1212.
13. Gottlieb GS, et al. 2009. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa. Clin. Infect. Dis. 48: 476-483.
14. Herschhorn A, Hizi A. 2010. Retroviral reverse transcriptases. Cell. Mol. Life Sci. 67:2717-2747.
15. Hizi A, Tal R, Shaharabany M, Loya S. 1991. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 266:6230-6239.
16. Huang H, Chopra R, Verdine GL, Harrison SC. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
17. Ibe S, Sugiura W. 2011. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol. 6:295-315.
18. Jain V, et al. 2011. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J. Infect. Dis. 203:1174-1181.
19. Jallow S, et al. 2009. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J. Clin. Microbiol. 47: 2200-2208.
20. Maeda Y, Venzon DJ, Mitsuya H. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177:1207-1213.
21. Martinez-Picado J, Martinez MA. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134:104-123.
22. Matamoros T, Nevot M, Martinez MA, Menendez-Arias L. 2009. Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination. J. Biol. Chem. 284:32792-32802.
23. Menendez-Arias L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146.
24. Ndembi N, et al. 2008. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J. Clin. Microbiol. 46:177-184.
25. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA. 2009. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob. Agents Chemother. 53:3611-3619.
26. Ntemgwa ML, et al. 2009. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 53:708-715.
27. Paredes R, et al. 2009. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J. Virol. 83:2038-2043.
28. Puertas MC, et al. 2009. Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. J. Virol. 83:7434-7439.
29. Ruelle J, et al. 2008. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect. Dis. 8:21.
30. Ruelle J, et al. 2007. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res. Hum. Retroviruses 23:955-964.
31. Sarafianos SG, Das K, Hughes SH, Arnold E. 2004. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 14:716-730.
32. Sarafianos SG, et al. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713.
33. Scarth B, McCormick S, Gotte M. 2011. Effects of mutations F61A and A62V in the fingers subdomain of HIV-1 reverse transcriptase on the translocational equilibrium. J. Mol. Biol. 405:349-360.
34. Smith AJ, Meyer PR, Asthana D, Ashman MR, Scott WA. 2005. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations. Antimicrob. Agents Chemother. 49:1761-1769.
35. Smith AJ, Scott WA. 2006. The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell. Curr. Pharm. Des. 12:1827-1841.
36. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS. 2009. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J. Infect. Dis. 199: 1323-1326.
37. Trevino A, et al. 2011. Drug resistance mutations in patients infected with HIV-2 living in Spain. J. Antimicrob. Chemother. 66:1484-1488.
38. Tu X, et al. 2010. Structural basis of HIV-1 resistance to AZT by excision. Nat. Struct. Mol. Biol. 17:1202-1209.
39. Ueno T, Shirasaka T, Mitsuya H. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. J. Biol. Chem. 270: 23605-23611.
40. Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH. 2011. 4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication. Antimicrob. Agents Chemother. 55:2379-2389.